返回
TransThera Sciences (Nanjing), Inc.（02617.HK）价格
02617.HK 股价走势图
TRANSTHERA-B (02617.HK)
TransThera Sciences (Nanjing), Inc.
HK$93.3
-2.3%
$-2.2
盘中： Jan 19, 15:01:45 HKT
暂无数据Earnings FAQ
02617.HK 最近的每股收益与预期相比如何？
TransThera Sciences (Nanjing), Inc. 02617.HK 上一季度的收入表现如何？
TransThera Sciences (Nanjing), Inc. 的收入预期是多少？
TransThera Sciences (Nanjing), Inc. 的盈利质量评分是多少？
TransThera Sciences (Nanjing), Inc. 何时发布财报？
TransThera Sciences (Nanjing), Inc. 的预期收益是多少？
TransThera Sciences (Nanjing), Inc. 是否超出收益预期？
关键数据
前收盘价
$95.5
开盘价
$95.5
当日区间
$93 - $97.95
52周范围
$20.2 - $679.5
交易量
461.0K
平均成交量
1.7M
每股收益（TTM）
-0.66
股息收益率
--
市值
$28.1B
什么是 TRANSTHERA-B？
TransThera Sciences (Nanjing), Inc. engages in the research and development of clinical biopharmaceutics. The company is headquartered in Nanjing, Jiangsu and currently employs 121 full-time employees. The company went IPO on 2025-06-23. The firm's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The firm's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). The company is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.